Evidence Hub

IL-17 Inhibitor Secukinumab Achieves Remission in Relapsing Polychondritis: A Case Report

Stefka Neycheva, Adriana Kamburova

The American journal of case reports, 2025

2 citations

Abstract

Patient: Female, 23-year-old Final Diagnosis: Relapsing polychondritis Symptoms: Auriculas were painful, edematous with severe hyperemia • sparing the earlobes Clinical Procedure: — Specialty: Rheumatology Objective: Diagnostic/therapeutic accidents Background: Relapsing polychondritis is a rare autoimmune disease of unknown etiology. There are no defined protocols for treatment, and its management depends on the physician’s knowledge and empirical experience. Various reports often highlight the insufficient efficacy of conventional disease-modifying anti-rheumatic drugs, and report controversial results associated with the use of different biologic agents. Case Report: The patient was a 32-year-old woman, previously diagnosed with ankylosing spondylitis. Four years after the initial diagnosis and following her second delivery, the patient presented with a refractory and aggressive relapsing polychondritis, which posed a significant challenge for treatment. Two months prior to the onset of the chondritis, the patient exhibited high disease activity of ankylosing spondylitis, with ASDAS-CRP 3.5 and BASDAI 6.0. After treatment failure using a combination of an anti-TNFα inhibitor and methotrexate, we achieved remission of both co-existing autoimmune diseases using an IL-17 inhibitor (secukinumab). Conclusions: Further investigations are needed to better understand the pathogenesis of this rare condition. The existence of various reports on the controversial effects of…

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free